Company profile

Eisai

Diversified pharma, neurology franchise

4523 · TSE · Japan

Public Market Listing

4523TSE

TSE primary exchange listing

Live quotes, historical charts, and market capitalization for Eisai are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(8 total)
8Total Assets
6Approved
2Phase 3 / Filed
0Phase 1–2 / Early
3Diseases
Quick filter:
Showing 8 of 8 assets
Target & Modality
Eribulin mesylate
Approved
Tubulin / microtubulesSmall molecule
HR+/HER2- Breast Cancer
HR+/HER2- Metastatic Breast Cancer
Lecanemab(Leqembi)
Approved
Amyloid-beta (monoclonal antibody)Monoclonal antibody
Alzheimer's Disease
Lemborexant(Dayvigo)
Approved
Orexin receptor (repositioned)Small molecule
Alzheimer's Disease
Perampanel(Fycompa)
Approved
AMPA receptor (antagonist) · AMPA receptor (positive allosteric modulator)Small molecule
Epilepsy
Rufinamide
Approved
Voltage-gated sodium channelSmall molecule
Epilepsy
Zonisamide (Zonegran)(Zonegran)
Approved
Voltage-gated sodium channelSmall molecule
Epilepsy
Etalanetug
Phase 3
Tau (monoclonal antibody)Monoclonal antibody
Alzheimer's Disease
H3B-6545
Phase 3
Estrogen receptor alpha (covalent antagonist)Small molecule
HR+/HER2- Breast Cancer
HR+/HER2- Metastatic Breast Cancer

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.